Clinical Trial Update: Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating alectinib in combination with nivolumab for recurrent or refractory hepatocellular carcinoma, guided by serum RNase1 and tumor PD-L1 ex…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Alecensa (alectinib)
• OPDIVO (nivolumab)

Snippet

Sponsor: China Medical University Hospital | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED